Bo Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Huang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Jie Liu
Key Laboratory for Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine, Zunyi Medical University, Zunyi, China
2 shared publications - Ai Ran
College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
1 shared publication - An-Ling Hu
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnocentric of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, 563000, China; State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou, 550025, China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, Guiyang, Guizhou, 550014, China
1 shared publication - Bin Xiao
College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China
1 shared publication - Bo Liu
Key Lab for Basic Pharmacology and Joint International Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
1 shared publication - Ce Liang
College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 253
The protection of chronic cerebral ischemia by Hua-Feng-Dan involves the modulation of hippocampal transcriptome and gut dysbiosis
The protective effects of Hua-Feng-Dan recipes against chronic cerebral hypoperfusion-induced ischemia were examined; RNA-seq and 16 S-rRNA-seq were used to explore the molecular mechanisms. Male Sprague-Dawley rats underwent unilateral common carotid artery ligation surgery to establish chronic cerebral hypoperfusion (CCH) models. Then, the CCH rats were treated with various Hua-Feng-Dan recipes in diet for 20 days. Finally, behavioral tests were performed, followed by histopathology. Hippocampal RNA was isolated for RNA-seq and RT-qPCR analyses; Colon bacterial DNA was isolated for 16 S rRNA-seq and bioinformatics. The CCH rats exhibited cognition deficits evidenced by Behavioral tests. The neurons in the hippocampus CA1 area were damaged. Hua-Feng-Dan recipes as Reduced_H (0.5 g/kg), Original, and Nonferment improved behavioral deficits and morphological changes, while Reduced_L (0.25 g/kg) was ineffective. RNA-seq revealed distinct gene expression pattern among groups. Ingenuity pathway analysis of differentially expressed genes revealed Hua-Feng-Dan recipes ameliorated Canonical pathways involved in cytosolic Ca 2+ overload, disruption of IGF homeostasis and Neutrophil degranulation; attenuated CCH-activated Upstream regulators such as IL1B, IL6, TNF, IGF1, and glucose metabolism. CCH-decreased Firmicutes/Bacteroidetes ratio were recovered by Hua-Feng-Dan recipes. CCH-increased Prevotellaceae and decreased Lachnospiraceae were attenuated; CCH-increased ASV1 and decreased ASV39 were brought to normal after Hua-Feng-Dan treatments. Similar to the efficacy against CCH, Reduced_L was ineffective in transcriptome and gut microbiota analysis. Hua-Feng-Dan recipes (Reduced_H, Original, and Nonferment) are effective against CCH-induced chronic cerebral ischemia, while Reduced_L was ineffective. The mechanisms of the protection are related to transcriptome regulation in the hippocampus, and modulation of CCH-disrupted gut dysbiosis.
- 9 November 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 253
Open AccessThe protection of chronic cerebral ischemia by Hua-Feng-Dan involves the modulation of hippocampal transcriptome and gut dysbiosis
The protective effects of Hua-Feng-Dan recipes against chronic cerebral hypoperfusion-induced ischemia were examined; RNA-seq and 16 S-rRNA-seq were used to explore the molecular mechanisms. Male Sprague-Dawley rats underwent unilateral common carotid artery ligation surgery to establish chronic cerebral hypoperfusion (CCH) models. Then, the CCH rats were treated with various Hua-Feng-Dan recipes in diet for 20 days. Finally, behavioral tests were performed, followed by histopathology. Hippocampal RNA was isolated for RNA-seq and RT-qPCR analyses; Colon bacterial DNA was isolated for 16 S rRNA-seq and bioinformatics. The CCH rats exhibited cognition deficits evidenced by Behavioral tests. The neurons in the hippocampus CA1 area were damaged. Hua-Feng-Dan recipes as Reduced_H (0.5 g/kg), Original, and Nonferment improved behavioral deficits and morphological changes, while Reduced_L (0.25 g/kg) was ineffective. RNA-seq revealed distinct gene expression pattern among groups. Ingenuity pathway analysis of differentially expressed genes revealed Hua-Feng-Dan recipes ameliorated Canonical pathways involved in cytosolic Ca 2+ overload, disruption of IGF homeostasis and Neutrophil degranulation; attenuated CCH-activated Upstream regulators such as IL1B, IL6, TNF, IGF1, and glucose metabolism. CCH-decreased Firmicutes/Bacteroidetes ratio were recovered by Hua-Feng-Dan recipes. CCH-increased Prevotellaceae and decreased Lachnospiraceae were attenuated; CCH-increased ASV1 and decreased ASV39 were brought to normal after Hua-Feng-Dan treatments. Similar to the efficacy against CCH, Reduced_L was ineffective in transcriptome and gut microbiota analysis. Hua-Feng-Dan recipes (Reduced_H, Original, and Nonferment) are effective against CCH-induced chronic cerebral ischemia, while Reduced_L was ineffective. The mechanisms of the protection are related to transcriptome regulation in the hippocampus, and modulation of CCH-disrupted gut dysbiosis.
- Open Access
RNA Binding Protein PTBP1 Promotes the Metastasis of Gastric Cancer by Stabilizing PGK1 mRNA
Gastric cancer (GC) is the most common type of malignant tumor within the gastrointestinal tract, and GC metastasis is associated with poor prognosis. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein implicated in various types of tumor development and metastasis. However, the role of PTBP1 in GC metastasis remains elusive. In this study, we verified that PTBP1 was upregulated in GC tissues and cell lines, and higher PTBP1 level was associated with poorer prognosis. It was shown that PTBP1 knockdown in vitro inhibited GC cell migration, whereas PTBP1 overexpression promoted the migration of GC cells. In vivo, the knockdown of PTBP1 notably reduced both the size and occurrence of metastatic nodules in a nude mice liver metastasis model. We identified phosphoglycerate kinase 1 (PGK1) as a downstream target of PTBP1 and found that PTBP1 increased the stability of PGK1 by directly binding to its mRNA. Furthermore, the PGK1/SNAIL axis could be required for PTBP1’s function in the promotion of GC cell migration. These discoveries suggest that PTBP1 could be a promising therapeutic target for GC.
Open AccessRNA Binding Protein PTBP1 Promotes the Metastasis of Gastric Cancer by Stabilizing PGK1 mRNA
Gastric cancer (GC) is the most common type of malignant tumor within the gastrointestinal tract, and GC metastasis is associated with poor prognosis. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein implicated in various types of tumor development and metastasis. However, the role of PTBP1 in GC metastasis remains elusive. In this study, we verified that PTBP1 was upregulated in GC tissues and cell lines, and higher PTBP1 level was associated with poorer prognosis. It was shown that PTBP1 knockdown in vitro inhibited GC cell migration, whereas PTBP1 overexpression promoted the migration of GC cells. In vivo, the knockdown of PTBP1 notably reduced both the size and occurrence of metastatic nodules in a nude mice liver metastasis model. We identified phosphoglycerate kinase 1 (PGK1) as a downstream target of PTBP1 and found that PTBP1 increased the stability of PGK1 by directly binding to its mRNA. Furthermore, the PGK1/SNAIL axis could be required for PTBP1’s function in the promotion of GC cell migration. These discoveries suggest that PTBP1 could be a promising therapeutic target for GC.
- Open Access
- 15 January 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-8
Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II
Cardiac hypertrophy is a major pathological process to result in heart failure and sudden death. Rutaecarpine, a pentacyclic indolopyridoquinazolinone alkaloid extracted from Evodia rutaecarpa with multiple pharmacological activities, yet the underlying protective effects and the mechanisms on cardiac hypertrophy remain unclear. This study aimed to evaluate the potential effects of rutaecarpine on pressure overload cardiac hypertrophy. Cardiac hypertrophy in rat was developed by abdominal aortic constriction (AAC) for 4 weeks, which was improved by rutaecarpine supplementation (20 or 40mg/kg/day, i.g.) for another 4 weeks. The level of angiotensin II was increased; the mRNA expression and the activity of calcineurin in the left ventricular tissue were augmented following cardiac hypertrophy. Rutaecarpine administration decreased angiotensin II content and reduced calcineurin expression and activity. Noteworthily, in angiotensin II-induced cardiomyocytes, rutaecarpine ameliorated the hypertrophic effects in a dose-dependent manner and downregulated the increased mRNA expression and activity of calcineurin. In conclusion, rutaecarpine can improve cardiac hypertrophy in pressure overload rats, which may be related to the inhibition of angiotensin II-calcineurin signal pathway.
- 15 January 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-8
Open AccessRutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II
Cardiac hypertrophy is a major pathological process to result in heart failure and sudden death. Rutaecarpine, a pentacyclic indolopyridoquinazolinone alkaloid extracted from Evodia rutaecarpa with multiple pharmacological activities, yet the underlying protective effects and the mechanisms on cardiac hypertrophy remain unclear. This study aimed to evaluate the potential effects of rutaecarpine on pressure overload cardiac hypertrophy. Cardiac hypertrophy in rat was developed by abdominal aortic constriction (AAC) for 4 weeks, which was improved by rutaecarpine supplementation (20 or 40mg/kg/day, i.g.) for another 4 weeks. The level of angiotensin II was increased; the mRNA expression and the activity of calcineurin in the left ventricular tissue were augmented following cardiac hypertrophy. Rutaecarpine administration decreased angiotensin II content and reduced calcineurin expression and activity. Noteworthily, in angiotensin II-induced cardiomyocytes, rutaecarpine ameliorated the hypertrophic effects in a dose-dependent manner and downregulated the increased mRNA expression and activity of calcineurin. In conclusion, rutaecarpine can improve cardiac hypertrophy in pressure overload rats, which may be related to the inhibition of angiotensin II-calcineurin signal pathway.
- 1 October 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 260, 113046
Ginsenoside Rg1 prevents vascular intimal hyperplasia involved by SDF-1α/CXCR4, SCF/c-kit and FKN/CX3CR1 axes in a rat balloon injury
- 1 October 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 260, 113046
Ginsenoside Rg1 prevents vascular intimal hyperplasia involved by SDF-1α/CXCR4, SCF/c-kit and FKN/CX3CR1 axes in a rat balloon injury
- 1 January 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 819, 68-79
IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway
- 1 January 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 819, 68-79
IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway